Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

jadran galenski laboratorij d.d. - xylometazoline (xylometazoline hydrochloride) - spray nasal - 0,5mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

jadran galenski laboratorij d.d. - xylometazoline (xylometazoline hydrochloride) - spray nasal - 1mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

jadran-galenski laboratorij d.d. - xylometazoline (xylometazoline hydrochloride) - spray nasal - 1mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

jadran-galenski laboratorij d.d. - xylometazoline (xylometazoline hydrochloride) - spray nasal - 0,5mg/ml

European Union - English - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Australia - English - Department of Health (Therapeutic Goods Administration)

ikaria australia pty ltd - nitric oxide, quantity: 0.08 % w/w - gas, medicinal - excipient ingredients: nitrogen - inomax?, in conjunction with ventilatory support and other appropriate agents, is indicated -,- for the treatment of term and near-term ( greater than 34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.,- to selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension in conjunction with heart surgery

Australia - English - Department of Health (Therapeutic Goods Administration)

nitric oxide -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis consumer health s.a, switzerland - oral solution - 15 ml - sodium chloride solution

United States - English - NLM (National Library of Medicine)

ino therapeutics llc - nitric oxide (unii: 31c4ky9esh) (nitric oxide - unii:31c4ky9esh) - nitric oxide 0.98 mg in 1 l - inomax® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. inomax is contraindicated in neonates dependent on right-to-left shunting of blood. the safety and efficacy of nitric oxide for inhalation has been demonstrated in term and near-term neonates with hypoxic respiratory failure associated with evidence of pulmonary hypertension [see clinical studies (14.1)]. additional studies conducted in premature neonates for the prevention of bronchopulmonary dysplasia have not demonstrated substantial evidence of efficacy [see clinical studies (14.3)]. no information about its effectiveness in other age populations is available. nitric oxide is not indicated for use in the adult population.

Canada - English - Health Canada

ultragenyx pharmaceutical inc - triheptanoin - liquid - 100% - triheptanoin 100% - caloric agents